SanofiSNY
About: Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Employees: 82,878
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
90% more first-time investments, than exits
New positions opened: 114 | Existing positions closed: 60
39% more repeat investments, than reductions
Existing positions increased: 299 | Existing positions reduced: 215
14% more capital invested
Capital invested by funds: $12.8B [Q4 2024] → $14.5B (+$1.73B) [Q1 2025]
9% more funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 12 (+1) [Q1 2025]
5% more funds holding
Funds holding: 711 [Q4 2024] → 748 (+37) [Q1 2025]
6% more call options, than puts
Call options by funds: $102M | Put options by funds: $96M
0.27% more ownership
Funds ownership: 20.91% [Q4 2024] → 21.17% (+0.27%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for SNY.
Financial journalist opinion
Based on 29 articles about SNY published over the past 30 days
